Categories: News

Financière de Tubize – Annual report 2024

FacebookFacebookTwitterTwitterEmailEmailLinkedInLinkedInWhatsAppWhatsAppMessengerMessengerFlipboardFlipboardGmailGmailTelegramTelegramShareShare

Annual Report 2024
Regulated information 22 March 2025

The board of directors of Financière de Tubize has established the 2024 annual report. This report is available on the website www.financiere-tubize.be

  • Profit for the financial year: € 90.1 million (€ 88.2 million in 2023, + 2,2%),
  • Reduction of outstanding bank borrowings from € 79.2 million at 31 December 2023 to € 41.3 million at 31 December 2024,
  • Acquisition, in 2024, of 53,706 UCB shares, increasing the holding of the Company in UCB from 36.24% on 31 December 2023 to 36.27% on 31 December 2024.

If the general shareholders meeting of 25 April 2025 approves the 2024 annual accounts, including the proposed result appropriation, a gross dividend of € 1.04 (compared to €0.97 for financial year 2023, an increase of 7.2%) will be payable as from 5 May 2025 onwards at the offices, seats and branches of BNP Paribas Fortis, in exchange of coupon n° 20.

Ex-dividend           30 April 2025
Record date             2 May 2025
Payment date          5 May 2025

FacebookFacebookTwitterTwitterEmailEmailLinkedInLinkedInWhatsAppWhatsAppMessengerMessengerFlipboardFlipboardGmailGmailTelegramTelegramShareShare
AddThis Website Tools
Staff

Recent Posts

AMBOSS closes €240M financing round and expands its position as the leading co-pilot for physicians worldwide

BERLIN and NEW YORK, March 25, 2025 /PRNewswire/ -- AMBOSS, the leading resource for medical…

21 minutes ago

Medit Launches Medit i900 classic, a New Addition to Medit i900 Family Line Up

SEOUL, South Korea and NEWPORT BEACH, Calif., March 25, 2025 /PRNewswire/ -- Medit (www.medit.com), a…

21 minutes ago

Optimind Pharma Enters into Letter of Intent with Monjin to Acquire AI Business

Toronto, Ontario--(Newsfile Corp. - March 24, 2025) - Optimind Pharma Corp. (CSE: OMND) (the "Optimind"…

6 hours ago

In-Licensing Opportunity: How a Pharma Leader Leveraged Scientific Innovation for Clinical and Commercial Success | DelveInsight

A leading U.S.-based drug delivery device company known for its strong global commercial presence recognized…

12 hours ago

Azenta Publishes its 2024 Environmental, Social, & Governance (ESG) Report

BURLINGTON, Mass., March 24, 2025 /PRNewswire/ -- Azenta, Inc. (Nasdaq: AZTA) today announced the publication…

12 hours ago

OpenLight Achieves Successful Completion of Telcordia GR-468 Qualification for Silicon Photonics Components

Milestone in optoelectronics provides significant assurance in the design and manufacturing process of advanced optoelectronic…

12 hours ago